���Ҵ�ý�ƽ������

Think Bioscience (“Think”), a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, has raised $17M in an oversubscribed Seed round. Think's foundational IP was developed by CEO Jerome Fox's research group at ���Ҵ�ý�ƽ������.

SomaLogic, a leader in AI data-driven proteomics technology founded by Professor Larry Gold (MCDB), has entered into an agreement to acquire Palamedrix, Inc.—a move intended to accelerate the SomaScan Platform's utilization in global biopharma and academic markets.

“For the industry, now is the time to solve this problem,” Wil Srubar, an associate professor at ���Ҵ�ý�ƽ������ and the lead researcher on the project, says in a news release. “We believe that we have one of the best solutions, if not the best solution, for the cement and concrete industry to address its carbon problem.”

The merger is addressing pressing needs in quantum research for ���Ҵ�ý�ƽ������ spinout ColdQuanta—as well as the quantum industry. Both companies are affiliates of Q-NEXT, a U.S. Department of Energy (DOE) National Quantum Information Science Research Center led by Argonne National Laboratory.

Air traffic congestion due to weather hazards causes millions of dollars in lost airline profit each year. This new method of determining optimum flow patterns for airplanes combines weather data with historical air traffic data to ensure efficient planning and reduced traffic constriction.

Researchers at ���Ҵ�ý�ƽ������ have developed a novel process for producing high-purity CBDA. Since CBDA rapidly breaks down, it can be difficult to isolate. This process converts CBD to CBDA in a single step. The end result is desirable for researchers as it is chemically pure, odorless and colorless.